CD33 epitope-engineered blood stem cell graft (ExCellThera)

N/A

Report date: 2025/08/14 17:46:52

Base Information

Drug NameCD33 epitope-engineered blood stem cell graft (ExCellThera)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsStem cell replacements
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExcellthera Inc
China Registration ClassN/A

Develop Information

Active CompaniesExcellthera Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A